Novaliq’s Miebo approved for Dry Eye

Dry Eye drops approved by FDA in USA

FDA Approves Bausch + Lomb and Novaliq’s Miebo for the Treatment of the Signs and Symptoms of Dry Eye Disease

Bausch + Lomb announced last Thursday that the FDA has approved Miebo (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) for the treatment of the signs and symptoms of dry eye disease (DED). The companies  say Miebo is the first and only FDA-approved treatment for DED that directly targets tear evaporation.

Miebo, which is administered as a single drop into each eye and is given four times a day, is designed to reduce tear evaporation at the ocular surface.

“Today’s FDA approval of Miebo further advances DED treatment by addressing a significant unmet need for millions of people suffering with this disease,” Brent Saunders, chairman and CEO of Bausch + Lomb, said in a company news release. “We are proud to bring to market the first and only prescription eye drop approved in the United States for the treatment of DED that directly targets evaporation. We expect to make Miebo commercially available in the second half of this year.”

The approval marks the first prescription eye treatment to be approved by the FDA since Bausch + Lomb became an independent, publicly traded eye health company last May.